Thursday, April 21, 2016

BRIEF-Biomarin enrolls first patient in early study of BMN 250 for sanfilippo B syndrome

* Biomarin enrolls first patient in phase 1/2 trial of NAGLU

fusion protein BMN 250 for treatment of MPS IIIB (sanfilippo B

syndrome)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)